Angelini Pharma Deal History & Licensing Activity
Angelini Pharma is a life sciences. Over the past three years, Angelini Pharma has been involved in 5 licensing and acquisition transactions, with a primary focus on Small Molecules (7 deals).
Deals (12mo)
4
Active Trials
0
Top Modality
Small Molecules
Focus Area
Mega Deals
Angelini Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Angelini Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Catalyst CNS rare neuro portfolio | Angelini | Other | Approved | acquisition | May 2026 |
| Firdapse (amifampridine) | Catalyst Pharmaceuticals | Small Molecules | Approved | acquisition | May 2026 |
| Firdapse (amifampridine) | Catalyst Pharmaceuticals | Small Molecules | Approved | acquisition | May 2026 |
Angelini Pharma Pipeline Focus
Therapeutic areas and modalities where Angelini Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Angelini Pharma's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Angelini Pharma Licensing & Deal Activity
Angelini Pharma is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Angelini Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Angelini Pharma include Mega Deals (8 deals and trials), and Neurology (1 deal and trial). In terms of modality, Angelini Pharma has shown particular interest in small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Angelini Pharma and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Angelini Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.